EP3498704A4 - CRYSTAL OF A LONG-TERM DPP-IV INHIBITOR AND SALT THEREOF - Google Patents
CRYSTAL OF A LONG-TERM DPP-IV INHIBITOR AND SALT THEREOF Download PDFInfo
- Publication number
- EP3498704A4 EP3498704A4 EP17838796.5A EP17838796A EP3498704A4 EP 3498704 A4 EP3498704 A4 EP 3498704A4 EP 17838796 A EP17838796 A EP 17838796A EP 3498704 A4 EP3498704 A4 EP 3498704A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- dpp
- salt
- crystal
- long
- acting inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610666564 | 2016-08-12 | ||
CN201610665625 | 2016-08-12 | ||
PCT/CN2017/097046 WO2018028666A1 (zh) | 2016-08-12 | 2017-08-11 | Dpp-iv长效抑制剂的结晶及其盐 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3498704A1 EP3498704A1 (en) | 2019-06-19 |
EP3498704A4 true EP3498704A4 (en) | 2020-03-04 |
Family
ID=61162770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17838796.5A Withdrawn EP3498704A4 (en) | 2016-08-12 | 2017-08-11 | CRYSTAL OF A LONG-TERM DPP-IV INHIBITOR AND SALT THEREOF |
Country Status (9)
Country | Link |
---|---|
US (1) | US10822319B2 (ko) |
EP (1) | EP3498704A4 (ko) |
JP (1) | JP6997760B2 (ko) |
KR (1) | KR20190039754A (ko) |
CN (1) | CN109874304B (ko) |
AU (1) | AU2017308691B2 (ko) |
CA (1) | CA3033890A1 (ko) |
RU (1) | RU2753335C9 (ko) |
WO (1) | WO2018028666A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108456196A (zh) * | 2017-02-22 | 2018-08-28 | 四川科伦博泰生物医药股份有限公司 | 3-氨基四氢吡喃衍生物的盐及其多晶型、其制备方法和用途 |
CN111793071B (zh) * | 2020-07-06 | 2021-06-04 | 四川凯科医药科技有限公司 | 奥格列汀的合成工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007097931A2 (en) * | 2006-02-15 | 2007-08-30 | Merck & Co., Inc. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2010056708A1 (en) * | 2008-11-13 | 2010-05-20 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1261928A2 (en) * | 1999-12-02 | 2002-12-04 | General Electric Company | System and method for valuing loan portfolios using fuzzy clustering |
CA2838738A1 (en) * | 2011-06-29 | 2013-01-03 | Merck Sharp & Dohme Corp. | Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor |
US9937153B2 (en) * | 2013-08-30 | 2018-04-10 | Merck Sharp & Dohme Ltd. | Oral pharmaceutical formulation of omarigliptin |
CN105985357A (zh) * | 2015-02-12 | 2016-10-05 | 北京赛林泰医药技术有限公司 | 取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂 |
WO2017031918A1 (zh) | 2015-08-24 | 2017-03-02 | 四川科伦药物研究院有限公司 | 长效二肽基肽酶-iv抑制剂、用途及其中间体的制备方法 |
-
2017
- 2017-08-11 EP EP17838796.5A patent/EP3498704A4/en not_active Withdrawn
- 2017-08-11 US US16/324,884 patent/US10822319B2/en active Active
- 2017-08-11 CN CN201780044045.0A patent/CN109874304B/zh active Active
- 2017-08-11 AU AU2017308691A patent/AU2017308691B2/en not_active Expired - Fee Related
- 2017-08-11 RU RU2019105352A patent/RU2753335C9/ru active
- 2017-08-11 WO PCT/CN2017/097046 patent/WO2018028666A1/zh unknown
- 2017-08-11 CA CA3033890A patent/CA3033890A1/en not_active Abandoned
- 2017-08-11 JP JP2019506673A patent/JP6997760B2/ja active Active
- 2017-08-11 KR KR1020197006819A patent/KR20190039754A/ko not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007097931A2 (en) * | 2006-02-15 | 2007-08-30 | Merck & Co., Inc. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2010056708A1 (en) * | 2008-11-13 | 2010-05-20 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
Non-Patent Citations (1)
Title |
---|
See also references of WO2018028666A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN109874304A (zh) | 2019-06-11 |
JP6997760B2 (ja) | 2022-01-18 |
EP3498704A1 (en) | 2019-06-19 |
US20190284153A1 (en) | 2019-09-19 |
RU2753335C9 (ru) | 2021-09-20 |
JP2019527708A (ja) | 2019-10-03 |
US10822319B2 (en) | 2020-11-03 |
RU2019105352A (ru) | 2020-09-14 |
KR20190039754A (ko) | 2019-04-15 |
RU2753335C2 (ru) | 2021-08-13 |
AU2017308691B2 (en) | 2021-12-16 |
AU2017308691A1 (en) | 2019-03-28 |
CN109874304B (zh) | 2021-06-25 |
CA3033890A1 (en) | 2018-02-15 |
WO2018028666A1 (zh) | 2018-02-15 |
RU2019105352A3 (ko) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3429591A4 (en) | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE | |
EP3684361A4 (en) | MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE | |
EP3529235A4 (en) | DOUBLE VISTA AND PD -1 CHANNEL INHIBITORS | |
EP3600318A4 (en) | METHODS FOR USING EHMT2 INHIBITORS | |
EP3510040A4 (en) | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE | |
EP3436455A4 (en) | NOVEL SALTS AND CRYSTALS | |
EP3558998A4 (en) | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE | |
EP3193876A4 (en) | Crystal forms of glutaminase inhibitors | |
EP3250035A4 (en) | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | |
EP3269719A4 (en) | Crystal form of jak inhibitor and preparation method thereof | |
IL273579A (en) | Salts of pyrrolothrizine compounds used as tem inhibitors. | |
EP3184520A4 (en) | Salt of monocyclic pyridine derivative and crystal thereof | |
EP3458448A4 (en) | METHOD OF USE OF FASN INHIBITORS | |
EP3057965A4 (en) | Salt and crystal forms of plk-4 inhibitor | |
EP3205653A4 (en) | Crystal form of bisulfate of jak inhibitor and preparation method therefor | |
EP3725786A4 (en) | CRYSTAL SHAPE AND SALT SHAPE OF A TGF-BRI INHIBITOR AND METHOD OF MANUFACTURING IT | |
EP3498704A4 (en) | CRYSTAL OF A LONG-TERM DPP-IV INHIBITOR AND SALT THEREOF | |
EP3476835A4 (en) | QUINOLEIN DERIVATIVE CRYSTAL | |
EP3370763A4 (en) | CD200 INHIBITORS AND METHODS OF USE | |
EP3269710A4 (en) | Nintedanib diethanesulfonate salt crystal and preparation method and use thereof | |
PT3725791T (pt) | Sal que serve como inibidor de akt e seu cristal | |
EP3505516A4 (en) | QUINAZOLINE DERIVATIVE SALT CRYSTAL | |
EP3433243B8 (en) | Novel derivatives and their use as selective inhibitors of caspase-2 | |
EP3279182A4 (en) | Acetylsalicylic acid derivative crystal and preparation method and use thereof | |
IL274274A (en) | Salt form and crystal form of compound as FGFR4 inhibitor and method of their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190312 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200203 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/12 20060101ALI20200128BHEP Ipc: A61P 3/00 20060101ALI20200128BHEP Ipc: A61P 25/00 20060101ALI20200128BHEP Ipc: A61P 5/50 20060101ALI20200128BHEP Ipc: A61K 31/4035 20060101ALI20200128BHEP Ipc: C07D 405/04 20060101AFI20200128BHEP Ipc: A61P 35/00 20060101ALI20200128BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210319 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20221027 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230301 |